We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., April 1, 2024 WALTHAM, Mass., April 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...
Spyre Therapeutics Announces $180 Million Private Placement PR Newswire WALTHAM, Mass., March 18, 2024 WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the...
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., March 1, 2024 WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Feb. 29, 2024 Announced corporate name change to Spyre...
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference PR Newswire WALTHAM, Mass., Feb. 26, 2024 WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.54 | -1.58357771261 | 34.1 | 35.88 | 31.27 | 259225 | 32.97682207 | CS |
| 4 | -4.26 | -11.2638815442 | 37.82 | 40.835 | 31.27 | 318240 | 35.53338921 | CS |
| 12 | 7.93 | 30.9403043309 | 25.63 | 47.97 | 20.07 | 512486 | 33.62196697 | CS |
| 26 | 22.75 | 210.453283996 | 10.81 | 47.97 | 10.42 | 384892 | 30.75630675 | CS |
| 52 | 22.75 | 210.453283996 | 10.81 | 47.97 | 10.42 | 384892 | 30.75630675 | CS |
| 156 | 22.75 | 210.453283996 | 10.81 | 47.97 | 10.42 | 384892 | 30.75630675 | CS |
| 260 | 22.75 | 210.453283996 | 10.81 | 47.97 | 10.42 | 384892 | 30.75630675 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
